{
  "docId": "019dd923-5fec-763b-95cd-961b6879cda6",
  "docSlug": "njj0K6xhOdjDOAwq28MP",
  "documentTitle": "See the 39-slide presentation that Moderna used to win over investors on its way to becoming the hottest company in biotech",
  "authorId": "Pitchdecks",
  "authorName": "Moderna",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.29,
  "pageNumber": 26,
  "pageCount": 39,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a standard pharmaceutical pipeline table format.",
  "elementsJson": [
    "data_table",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5fec-763b-95cd-961b6879cda6/26",
  "deckHref": "/decks/019dd923-5fec-763b-95cd-961b6879cda6",
  "deckJsonHref": "/decks/019dd923-5fec-763b-95cd-961b6879cda6.json",
  "deckAnchorHref": "/decks/019dd923-5fec-763b-95cd-961b6879cda6#slide-26",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "disclaimer",
      "text": "Abbreviations: GLP = good laboratory practice; IND = investigational new drug; CTA = clinical trial authorization; CMV = cytomegalovirus; CV = cardiovascular; HMPV = human metapneumovirus; PIV3 = parainfluenza virus 3; IL-12 = interleukin-12; VEGF-A = vascular endothelial growth factor A.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fe96e777-db7e-4608-9c1b-721a02ffd728",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.9,
        "x": 0.05,
        "y": 0.215
      },
      "kind": "table",
      "text": "Development Candidate (DC) | Lead | Indication / Target | Formulation | GLP Toxicology | IND/CTA Filed | Ph I | Ph 2 | Funding",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "54036e17-67fd-483e-aada-f35aedd37a21",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.6,
        "x": 0.06,
        "y": 0.08
      },
      "kind": "title",
      "text": "Our Pipeline – Cytomegalovirus (CMV) mRNA-1647",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "09dec6a1-3f55-4023-88d0-85ffa4551796",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "10ea1646-bb23-455f-87d4-8f853b6a6599",
      "evidence": "Pipeline table structure representing development stages over time",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}